Title: Ask the experts: Answering your questions on DMPA use and weight.

POPLINE Document Number: 281891

Source citation:

Contraceptive Technology Update, 2004 Dec;25(12):[2] p..

Abstract:

Should a woman who is obese and continues to gain weight on Depo-Provera [depot medroxyprogesterone acetate (DMPA), Pfizer, New York City] be allowed to continue its use if she so desires? Are providers contributing to the health risk of obesity by allowing a woman to do so? These questions are addressed by two members of the Contraceptive Technology Update editorial advisory board: Robert Hatcher, MD, MPH, professor of gynecology and obstetrics at Emory University School of Medicine in Atlanta, and Andrew Kaunitz, MD, professor and assistant chair in the obstetrics and gynecology department at the University of Florida Health Science Center/Jacksonville. (excerpt)

Keywords:

United States
Florida
Women
Obesity
Depo-Provera
Injectables
Contraceptive Implants
Risk Factors
Body Weight
North America
Americas
Developed Countries
Demographic Factors
Population
Physiology
Biology
Medroxyprogesterone Acetate
Contraceptive Agents, Progestin
Contraceptive Agents, Female
Contraceptive Agents
Contraception
Family Planning
Contraceptive Methods